Adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country has reported initial results in the Journal of Clinical Oncology .

The trial, called INSIGhT, is still underway testing additional therapies.

None of the therapies tested so far improved overall survival of patients.

The study's other co-first authors were Eudocia Quant Lee from Dana-Farber and Isabel Arrillaga-Romany from Massachusetts General Hospital .

Rahman : "This trial is more streamlined, but it's also rigorous, which makes it more likely that it will produce more reliable answers".